A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

06 Feb 20265 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Extensive Stage-small Cell Lung Cancer · Phase 1 · Enrollment 123 · Sponsor: Daiichi Sankyo

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 06 Feb 2026. The item focuses on A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03). Open the detail page to review the full original feed content.